SEC Company Response from IGC Pharma, Inc. (IGC) (CIK 0001326205) (IGC) — Mar 30, 2017
IGC Pharma, Inc. (IGC) (CIK 0001326205)
Date: March 30, 2017 · CIK: 0001326205 · Accession: 0001185185-17-000711
AI Filing Summary & Sentiment
File numbers found in text: 001-32830
Show Raw Text
CORRESP 1 filename1.htm India Globalization Capital, Inc. 4336 Montgomery Avenue Bethesda, Maryland 20814 Phone: 301-983-0998 Fax: 240-465-0273 March 30, 2017 VIA EDGAR Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Attn: Mr. Russel Mancuso Branch Chief Office of Electronics and Machinery Re: India Globalization Capital, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 8, 2017 File No. 001-32830 Dear Mr. Mancuso: This letter is to inform you that India Globalization Capital, Inc. has cancelled the shareholders meeting for fiscal year ending March 31, 2016, that was to be held on March 31, 2017. We expect to reschedule the shareholders meeting at an appropriate time after the filing of the Company' Annual Report on Form 10-K for the fiscal year ending March 31, 2017. We will not be following up on the Preliminary Proxy on Schedule 14A filed on March 8, 2017 with a Definitive Proxy filing. We appreciate all your assistance and clarifications in this matter. Sincerely, Very truly yours, ss: India Globalization Capital, Inc. John Cherin, CFO, Treasurer, and Principal Accounting and Financial Officer cc: Mr. Caleb French, SEC Mr. Ram Mukunda, IGC CEO